Interim treatment regimens during the COVID-19 pandemic1
NHS England has published interim treatment changes1 to allow for greater flexibility in the management of cancer during COVID-19 pandemic to ensure clinicians have additional treatment options through this time.
It give the following recommendations regarding the management of melanoma:
- Give oral therapy as first-line treatment for BRAF positive patients in preference to immunotherapy to reduce admission for intravenous therapy.
- Stop immunotherapy doublet (ipilimumab and nivolumab) and switch to single agent nivolumab or pembrolizumab to reduce toxicity.
Reference
- NHS England interim treatment changes during the COVID-19 pandemic. Last updated 12 August 2020.
To download more visual summaries and complete the melanoma CPD course register to OnMedica and then click
'View full content'.
